IMAP
Financiado
Integrative mechanistic and multi omics Modelling of Antigen Presentation to pre...
Integrative mechanistic and multi omics Modelling of Antigen Presentation to predict epitope dynamics
The immune system can patrol cell status by recognising epitopes bound to Human Leukocyte Antigen class I (HLA-I) molecules and triggering cytotoxic T cell (CTL) activation. Epitopes arrive at the cell surface through several step...
The immune system can patrol cell status by recognising epitopes bound to Human Leukocyte Antigen class I (HLA-I) molecules and triggering cytotoxic T cell (CTL) activation. Epitopes arrive at the cell surface through several steps of the antigen processing and presentation pathway (APP). Despite major discoveries in the past decades, the precise dynamics of APP are still not fully understood. These dynamics, however, determine the types and quantities of epitopes and therefore regulate the CTL response.
The objective of my project is the development of an APP model from gene transcription to recognition by CTL clones that captures the underlying APP mechanisms and dynamics. Current approaches are mainly machine learning-based and focus only on parts of the APP. They neglect the underlying APP dynamics and do not elucidate novel mechanisms. Therefore, they fail to predict epitopes under altered cellular states such as infection. My project overcomes this pitfall by complementing large scale machine learning approaches with mechanistic modelling to comprehensively understand the APP and enable successful epitope prediction.
To achieve this goal, I will:
1) develop an APP integrated computational description that combines a mechanistic model of the APP (based on detailed quantitative in vitro data) with a large-scale machine learning-based multi-omics model;
2) apply the model in two therapeutic-relevant cellular systems – Measles virus infection and chemotherapy-induced senescence – resulting in the educated identification of canonical and non-canonical epitopes.
This project is at the cutting edge of the research with direct application in epitope discovery for therapies such as anti-cancer immunotherapy, vaccination against infection and modulatory immunotherapies against autoimmune diseases. The implemented computational framework will be made available to the community thereby providing a direct benefit to European scientific public and private sectors.
ver más
Duración del proyecto: 65 meses
Fecha Inicio: 2020-10-13
Fecha Fin: 2026-03-31
Fecha Fin: 2026-03-31
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2020-10-13
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-2020-STG:
ERC STARTING GRANTS
Cerrada
hace 5 años
Presupuesto
El presupuesto total del proyecto asciende a
1M€
Líder del proyecto
MAXPLANCKGESELLSCHAFT ZUR FORDERUNG DER WISSE...
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
319.50K€ |
Participante